Actively Recruiting

Age: 18Years - 70Years
All Genders
NCT05592717

A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis

Led by Tianjin Medical University · Updated on 2024-07-03

15

Participants Needed

1

Research Sites

199 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.

CONDITIONS

Official Title

A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female in good general health aged 18 to 70 years
  • Presence of unilateral or bilateral non-infectious uveitis affecting the posterior segment
  • Active inflammation before YUTIQ treatment, meeting at least one of these: 651+ anterior chamber cell and/or 651+ vitreous haze, fluorescein angiography leakages, OCT showing macular edema, or three or more relapses in one year
  • Steroids and immunosuppressive agents discontinued within 3 months after YUTIQ injection
Not Eligible

You will not qualify if you...

  • Corneal or lens opacity blocking fundus view or likely needing cataract surgery during the study
  • History of neurological symptoms suggesting central nervous system demyelinating disease
  • Prior intravitreal treatment with Retisert, ILUVIEN, or YUTIQ within 36 months before Day 1
  • Prior intravitreal treatment with OZURDEX, Triesence, or TRIVARIS within 12 weeks before Day 1
  • Peri-ocular or subtenon steroid treatment within 12 weeks before Day 1
  • Media opacity preventing retina and vitreous evaluation (e.g., vitreous hemorrhage)
  • Hypersensitivity to any ingredients in YUTIQ
  • Any systemic or eye condition making the subject unsuitable for the study
  • Pregnant or nursing females; females of childbearing potential unwilling or unable to use acceptable contraception from 14 days before Day 1 until study end

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, China, 300000

Actively Recruiting

Loading map...

Research Team

X

xiaomin Zhang

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here